

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, Washington, D.C. 20231 on February 28, 2002

David V. Upite 47,147
Name of Attorney/Agent Registration No.
David V. Upite
Signature of Attorney/Agent

#2
S/for
P&G Case 6843MRRC

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of :
LEDOUSSAL ET AL. : Confirmation No.:
Serial No. : Group Art Unit: 1625
Filed: February , 2002 : Examiner
For ANTIMICROBIAL QUINOLONES, THEIR COMPOSITIONS AND USES



INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made below in a Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

Copies of the cited references were previously cited by or submitted to the USPTO in prior application P&G Case No. 6843MR, U.S. Patent Application Serial No. 09/266,197, filed March 10, 1999 and P&G Case No. 6843MRR, U.S. Patent Application Serial No. 09/292,943, filed August 15, 2001. Applicants claim priority to said application under 35 U.S.C. §120. Accordingly, copies of those documents are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d).

This information disclosure statement is being submitted under 37 C.F.R. §1.97 (b)(3). Applicants have not received an Office Action on the merits in the present application. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter is enclosed to facilitate charging of the fee, if necessary.

Respectfully submitted,

By

David V. Upite
David V. Upite
Attorney or Agent for Applicant(s)
Registration No. 47,147
(513) 622-1825

Date: February 28, 2002
Mason, Ohio
6843MRRCIDS/lrs